events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT
strategies to reduce major adverse cardiovascular events, while balancing bleeding risk,
requires ongoing review of clinical trials. Appended, the focused update of the Canadian
Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines for the
use of APT provides recommendations on the following topics:(1) use of acetylsalicylic acid …